Literature DB >> 1685652

Markers for disease progression in intravenous drug users infected with HIV-1.

R Zangerle1, D Fuchs, G Reibnegger, P Fritsch, H Wachter.   

Abstract

We evaluated the number and percentage of CD4+ T cells, the ratio of CD4+ T cells to CD8+ T cells, the serum levels of beta 2- microglobulin and urinary levels of neopterin for their ability to predict disease progression (defined as clinical AIDS and/or oral candidiasis in combination with a CD4+ T cell count less than 400 x 10(6)/l). Thirty-eight intravenous drug users (IVDU) infected with HIV-1 without HIV-1-related symptoms were followed for a median observation period of 45 months. Cumulative incidence of disease progression was computed by the product-limit approach. The CD4+: CD8+ T-cell ratio (P = 0.001), the number (P = 0.002) and percentage (P = 0.05) of CD4+ T cells, and urinary neopterin (P = 0.007) were significant predictors for disease progression. Serum beta 2-microglobulin, which has been found to be of similar prognostic value as neopterin in homosexual men, did not show predictive power in this study of IVDU. The urinary neopterin concentrations obtained at entry of the study correlated with the values of the CD4+:CD8+ T-cell ratio and number and percentage of CD4+ T cells which were obtained at the end of the follow-up. These findings should help to identify, among HIV-1-infected IVDU, those at high risk of disease progression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1685652     DOI: 10.1097/00002030-199108000-00010

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  7 in total

Review 1.  Cytokines, plasma immune activation markers, and clinically relevant surrogate markers in human immunodeficiency virus infection.

Authors:  J L Fahey
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

2.  Soluble tumor necrosis factor alpha receptors (sTNF-Rs) in HIV-1-infected intravenous drug users: change in circulating sTNF-R type II level and survival for AIDS patients.

Authors:  F Ajello; R La Licata; M Lodato; F Vitale; F Bonura; R Valenti; M Bruno; N Romano
Journal:  Eur J Epidemiol       Date:  2000-03       Impact factor: 8.082

3.  Improving the prognostic value of CD4+ count using IgA and clinical signs in HIV-seropositive i.v. drug users.

Authors:  F Montella; P Pezzotti; F Di Sora; O Recchia; F Lauria; G Rezza
Journal:  Infection       Date:  1997 Mar-Apr       Impact factor: 3.553

4.  Predictors of survival in human immunodeficiency virus type 1-seropositive intravenous drug users.

Authors:  J B Page; S Lai; M A Fletcher; R Patarca; P C Smith; H C Lai; N G Klimas
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

5.  Differential Relationships among Circulating Inflammatory and Immune Activation Biomediators and Impact of Aging and Human Immunodeficiency Virus Infection in a Cohort of Injection Drug Users.

Authors:  Gregory D Kirk; Stewart Dandorf; Huifen Li; Yiyin Chen; Shruti H Mehta; Damani A Piggott; Joseph B Margolick; Sean X Leng
Journal:  Front Immunol       Date:  2017-10-19       Impact factor: 7.561

Review 6.  Immune activation and collateral damage in AIDS pathogenesis.

Authors:  Frank Miedema; Mette D Hazenberg; Kiki Tesselaar; Debbie van Baarle; Rob J de Boer; José A M Borghans
Journal:  Front Immunol       Date:  2013-09-26       Impact factor: 7.561

Review 7.  The Potential Role of Cannabinoids in Modulating Serotonergic Signaling by Their Influence on Tryptophan Metabolism.

Authors:  Marcel Jenny; Sebastian Schröcksnadel; Florian Überall; Dietmar Fuchs
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.